Carisma Therapeutics, Inc..
CARM.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Carisma Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. The company is pioneering the development of engineered macrophages, a type of immune cell, for the treatment of cancer. Their primary focus is on developing chi...Show More
Better Health for All
40
Carisma Therapeutics is a clinical-stage biopharmaceutical company entirely focused on developing therapies for serious diseases, including cancer, fibrosis, and autoimmune disorders.
1
Its entire pipeline, including CAR-Monocyte and CAR-Macrophage therapies, is in discovery, preclinical, or Phase 1 clinical trial stages, aiming to provide health benefits.
2
The company has no revenue from products with negative health impacts. Carisma Therapeutics has demonstrated significant investment in health innovation, with a collaboration with Moderna that included a $45 million upfront payment and potential milestone payments up to $253 million per product.
3
Moderna also nominated 10 additional oncology research targets in February 2025.
4
The company also provided a $250,695 grant to Columbia University for CAR-M therapy research.
5
Carisma Therapeutics conducts Phase 1 clinical trials for CT-0508 and CT-0525, with 20 patients in the CT-0508 trial and 5 subjects treated in the CT-0525 trial, and adheres to GCP requirements, IRB review, informed consent, and data monitoring committees.
6
However, the company's owned patents are expected to expire between 2033-2044, and licensed patents between 2034-2040, with no evidence of flexibility in patent enforcement or licensing for global health needs.
7
Fair Money & Economic Opportunity
0
No evidence available to assess Carisma Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The company has no mention of any regulatory actions, violations, fines, or compliance issues related to labor practices across the provided articles.
1
No specific, concrete data points are available for living wage coverage, CEO median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, insecure contract share, or health insurance coverage.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete evidence was found in the provided articles regarding Carisma Therapeutics, Inc.'s performance on fair trade and ethical sourcing KPIs. The articles discuss general industry trends, market data, and regulatory actions not specific to the company's supply chain practices, fair trade certifications, audit frequency, forced/child labor incidents, traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend.
1
Honest & Fair Business
-20
Carisma Therapeutics has a comprehensive whistleblower policy, communicated to employees, officers, and directors who must annually certify they have read and understood the Code of Business Conduct and Ethics, which includes the policy.
1
It provides a confidential and anonymous ethics hotline and a secure web form for reporting misconduct, including financial reporting improprieties.
2
The company explicitly states there will be no retaliation for good-faith reports, and the Audit Committee receives all concerns, with a record provided quarterly.
3
The company also has an anti-corruption policy that prohibits the use of company funds for gifts to government officials, except if compliant with law, insignificant, and not in expectation of action.
4
It explicitly prohibits bribes and kickbacks and references compliance with the Foreign Corrupt Practices Act.
5
Kind to Animals
0
No specific, concrete data points were found for Carisma Therapeutics, Inc. regarding its animal welfare practices, policies, or performance across any of the defined KPIs. The articles primarily discuss regulatory changes by the FDA concerning animal testing in the pharmaceutical industry, general survey results from life sciences professionals, and Carisma's delisting and wind-down of operations. While one article mentions Carisma's preclinical tests are performed in accordance with FDA's good laboratory practice regulations and the U.S. Department of Agriculture’s Animal Welfare Act, this is a statement of regulatory compliance rather than a specific policy or measurable action by the company related to reducing or replacing animal testing, or any other animal welfare KPI.
1
No War, No Weapons
0
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. The provided articles, which include financial reports, an audit committee charter, and a code of business conduct and ethics, consistently state that information related to arms contracts, military technology, sales to embargoed regimes, peacebuilding investment, conflict divestment, board oversight of defense, export end-user certificates, lobbying against arms control, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use screening, surveillance transparency, ethical red lines for weapons, exposure to controversial weapons, war risk audits, conflict partner reviews, defense divestment, conflict minerals, peace tech investment, conflict zone procurement, and ethical red lines compliance is either not applicable to its operations or no specific data was found.
1
Therefore, no KPIs can be scored based on the provided evidence.
Planet-Friendly Business
0
The provided articles do not contain any specific, quantitative data points for the Planet-Friendly Business KPIs.
1
While articles note that no regulatory actions, violations, fines, or compliance issues are mentioned,
2
this indicates an absence of information rather than a concrete data point of zero violations. Therefore, no KPIs can be scored based on the evidence provided.
Respect for Cultures & Communities
0
The provided articles focus on Carisma Therapeutics' strategic restructuring, financial updates, and research and development pipeline, including workforce reductions, paused R&D activities, and progress in clinical trials and collaborations. However, none of the articles contain specific, concrete data points or information relevant to any of the KPIs under the 'Respect for Cultures & Communities' ethical value.
1
Therefore, no KPIs can be scored based on the evidence provided.
Safe & Smart Tech
0
No evidence available to assess Carisma Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Carisma Therapeutics, Inc. on Zero Waste & Sustainable Products.